Nobel Prize Winner Otto Warburg theorized that cancer cells were low in oxygen due to a change in cellular respiration from using oxygen to using fermentation of sugar. But he was never able to develop a technique to get oxygen into the cells to change this process. In the late 1970’s Nobel prize winner Linus Pauling […]
Continue reading
A recent study performed by AstraZeneca and MedImmue reveals, provisionally, that a Phase III trial with the drug Imfinzi, also known as durvalumab, gives longer life to patients with advanced, inoperable, non-small cell lung cancer (NSCLC). The trial, known as PACIFIC Phase 3, tests Imfinzi in comparison to placebo drugs in patients […]
Continue reading
Dear Friends, So far 2018 has been a year of great gains in our treatment of cancer at The CHIPSA Hospital. The CHIPSA Approach™ has been a simple one; forget our ego and preconceived notions of what works in treating cancer and be open to all possibilities. This includes considering both natural and man made […]
Continue reading
Vallovax and CHIPSAIn October of 2017 Chipsa was introduced to Batu Biologics, a San Diego based Biotech company, whose mission aligned with Chipsa’s. How can we harness the power of the immune system to treat cancer? Batu Biologics presented us with a novel therapy. A blood based vaccine that sought to target what many see as […]
Continue reading
Batu Biologics announced today the appointment of Nobel Prize winner Dr. Bruce Beutler to the Company’s Scientific Advisory Board. “I am excited to work alongside the team assembled by Samuel Wagner and provide advice towards the development of new therapeutic approaches to the treatment of cancer” Dr. Beutler was awarded the Nobel Prize in 2011 […]
Continue reading
Immuno-oncology is set to become one of the most vital cancer treatments, rising up into the realms surgery, chemotherapy, radiotherapy, and other targeted therapies. From their study, “Pharma Focus Visual Analysis of Immuno-Oncology Development and Opportunities”, Global Data was able to reach a conclusion and has analyzed more than 4,000 clinical trials of over 800 […]
Continue readingA mouse study published in Cell Chemical Biology reveals that a new version of the foreign fat molecule alpha-galactosylceramide (a-GalCer) is very successful at inducing inflammatory and anti-tumor responses in humans. The results of this study may be helpful in creating treatments that will prevent the spread of cancer. Past studies have shown that synthetic-GalCer, […]
Continue reading
Summary Researchers at Johns Hopkins are developing a new method called ImmunoMap, a digital map that compares different types of T-cell receptors, the “antennas” found on the surface of T-cells that identify foreign substances in the body to trigger an immune response. ImmunoMap will eventually help physicians to predict which cancer patients will respond […]
Continue reading
Summary According to a recent study that appeared in the March 2018 volume of The Journal of Nuclear Medicine, scientists at Bristol-Meyers Squibb (BMS) are developing a new way for physicians to determine how cancer patients might respond to PD-1 (programmed cell death protein 1) and PD-L1 (programmed death-ligand 1) targeted treatments. Previously, the […]
Continue reading
CAR T-Cell, or chimeric antigen receptor immunotherapy was recently used in a study to see if it could help prevent the spread of metastatic cancer. In the study humanized CAR T-Cell was successful at killing tumor cells as well as preventing it from spreading. The treatment may be useful for treating other types of […]
Continue reading